Fenghai Zhou

Prof. Dr. Fenghai Zhou

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2024 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
YZYun-Feng Zhang
Yun-Feng Zhang
CZChuan Zhou
Chuan Zhou
SGSheng Guo
Sheng Guo
CWChao Wang
Chao Wang
JYJin Yang
Jin Yang
FZFenghai Zhou
Fenghai Zhou
Purpose: Bone metastasis is a significant contributor to morbidity and mortality in advanced prostate cancer, and early diagnosis is challenging due to its insidious onset. The use of machine learning to obtain prognostic information from pathological images has been highlighted. However, there is a limited understanding of the potential of early prediction of bone metastasis through the feature combination method from various sources. This study presents a method of integrating multimodal data to enhance the feasibility of early diagnosis of bone metastasis in prostate cancer. Methods and materials: Overall, 211 patients diagnosed with prostate cancer (PCa) at Gansu Provincial Hospital between January 2017 and February 2023 were included in this study. The patients were randomized (8:2) into a training group (n = 169) and a validation group (n = 42). The region of interest (ROI) were segmented from the three magnetic resonance imaging (MRI) sequences (T2WI, DWI, and ADC), and pathological features were extracted from tissue sections (hematoxylin and eosin [H&E] staining, 10 × 20). A deep learning (DL) model using ResNet 50 was employed to extract deep transfer learning (DTL) features. The least absolute shrinkage and selection operator (LASSO) regression method was utilized for feature selection, feature construction, and reducing feature dimensions. Different machine learning classifiers were used to build predictive models. The performance of the models was evaluated using receiver operating characteristic curves. The net clinical benefit was assessed using decision curve analysis (DCA). The goodness of fit was evaluated using calibration curves. A joint model nomogram was eventually developed by combining clinically independent risk factors. Results: The best prediction models based on DTL and pathomics features showed area under the curve (AUC) values of 0.89 (95% confidence interval [CI], 0.799–0.989) and 0.85 (95% CI, 0.714–0.989), respectively. The AUC for the best prediction model based on radiomics features and combining radiomics features, DTL features, and pathomics features were 0.86 (95% CI, 0.735–0.979) and 0.93 (95% CI, 0.854–1.000), respectively. Based on DCA and calibration curves, the model demonstrated good net clinical benefit and fit. Conclusion: Multimodal radiomics and pathomics serve as valuable predictors of the risk of bone metastases in patients with primary PCa.

14 March 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CZChuan Zhou
Chuan Zhou
YZYun-Feng Zhang
Yun-Feng Zhang
SGSheng Guo
Sheng Guo
YHYu-Qian Huang
Yu-Qian Huang
XQXiao-Ni Qiao
Xiao-Ni Qiao
FZFenghai Zhou
Fenghai Zhou
Purpose: Patients with advanced prostate cancer (PCa) often develop castration-resistant PCa (CRPC) with poor prognosis. Prognostic information obtained from multiparametric magnetic resonance imaging (mpMRI) and histopathology specimens can be effectively utilized through artificial intelligence (AI) techniques. The objective of this study is to construct an AI-based CRPC progress prediction model by integrating multimodal data.Methods and materials: Data from 399 patients diagnosed with PCa at three medical centers between January 2018 and January 2021 were collected retrospectively. We delineated regions of interest (ROIs) from 3 MRI sequences viz, T2WI, DWI, and ADC and utilized a cropping tool to extract the largest section of each ROI. We selected representative pathological hematoxylin and eosin (H&E) slides for deep-learning model training. A joint combined model nomogram was constructed. ROC curves and calibration curves were plotted to assess the predictive performance and goodness of fit of the model. We generated decision curve analysis (DCA) curves and Kaplan–Meier (KM) survival curves to evaluate the clinical net benefit of the model and its association with progression-free survival (PFS).Results: The AUC of the machine learning (ML) model was 0.755. The best deep learning (DL) model for radiomics and pathomics was the ResNet-50 model, with an AUC of 0.768 and 0.752, respectively. The nomogram graph showed that DL model contributed the most, and the AUC for the combined model was 0.86. The calibration curves and DCA indicate that the combined model had a good calibration ability and net clinical benefit. The KM curve indicated that the model integrating multimodal data can guide patient prognosis and management strategies.Conclusion: The integration of multimodal data effectively improves the prediction of risk for the progression of PCa to CRPC.

8 June 2023 in Discover Oncology
Verified
Journal Article
Open access
PDF file
CZChuan Zhou
Chuan Zhou
YHYu-Qian Huang
Yu-Qian Huang
MDMingxu Da
Mingxu Da
WJWeilin Jin
Weilin Jin
FZFenghai Zhou
Fenghai Zhou
By the year 2035 more than 4 billion people might be affected by obesity and being overweight. Adipocyte-derived Extracellular Vesicles (ADEVs/ADEV-singular) are essential for communication between the tumor microenvironment (TME) and obesity, emerging as a prominent mechanism of tumor progression. Adipose tissue (AT) becomes hypertrophic and hyperplastic in an obese state resulting in insulin resistance in the body. This modifies the energy supply to tumor cells and simultaneously stimulates the production of pro-inflammatory adipokines. In addition, obese AT has a dysregulated cargo content of discharged ADEVs, leading to elevated amounts of pro-inflammatory proteins, fatty acids, and carcinogenic microRNAs. ADEVs are strongly associated with hallmarks of cancer (proliferation and resistance to cell death, angiogenesis, invasion, metastasis, immunological response) and may be useful as biomarkers and antitumor therapy strategy. Given the present developments in obesity and cancer-related research, we conclude by outlining significant challenges and significant advances that must be addressed expeditiously to promote ADEVs research and clinical applications.

16 November 2024 in Urology
Verified
Journal Article
Closed access
FZFenghai Zhou
Fenghai Zhou
BGBaihong Guo
Baihong Guo
HLHaidi Lv
Haidi Lv
XZXiaofeng Zhang
Xiaofeng Zhang
YZYunfeng Zhang
Yunfeng Zhang
QLQiangzhao Liu
Qiangzhao Liu

20 July 2023 in Discover Oncology
Verified
Journal Article
Open access
PDF file
CZChuan Zhou
Chuan Zhou
YZYun-Feng Zhang
Yun-Feng Zhang
SGSheng Guo
Sheng Guo
DWDong Wang
Dong Wang
HLHao-Xuan Lv
Hao-Xuan Lv
FZFenghai Zhou
Fenghai Zhou
Purpose: Prostate cancer (PCa) with high Ki-67 expression and high Gleason Scores (GS) tends to have aggressive clinicopathological characteristics and a dismal prognosis. In order to predict the Ki-67 expression status and the GS in PCa, we sought to construct and verify MRI-based radiomics signatures. Methods and materials: We collected T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) images from 170 PCa patients at three institutions and extracted 321 original radiomic features from each image modality. We used support vector machine (SVM) and least absolute shrinkage and selection operator (LASSO) logistic regression to select the most informative radiomic features and built predictive models using up sampling and feature selection techniques. Using receiver operating characteristic (ROC) analysis, the discriminating power of this feature was determined. Subsequent decision curve analysis (DCA) assessed the clinical utility of the radiomic features. The Kaplan–Meier (KM) test revealed that the radiomics-predicted Ki-67 expression status and GS were prognostic factors for PCa survival. Result: The hypothesized radiomics signature, which included 15 and 9 selected radiomics features, respectively, was significantly correlated with pathological Ki-67 and GS outcomes in both the training and validation datasets. Areas under the curve (AUC) for the developed model were 0.813 (95% CI 0.681,0.930) and 0.793 (95% CI 0.621, 0.929) for the training and validation datasets, respectively, demonstrating discrimination and calibration performance. The model's clinical usefulness was verified using DCA. In both the training and validation sets, high Ki-67 expression and high GS predicted by radiomics using SVM models were substantially linked with poor overall survival (OS). Conclusions: Both Ki-67 expression status and high GS correlate with PCa patient survival outcomes; therefore, the ability of the SVM classifier-based model to estimate Ki-67 expression status and the Lasso classifier-based model to assess high GS may enhance clinical decision-making.

28 August 2024 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
CWChao Wang
Chao Wang
CZChuan Zhou
Chuan Zhou
YZYun-Feng Zhang
Yun-Feng Zhang
HHHan He
Han He
DWDong Wang
Dong Wang
FZFenghai Zhou
Fenghai Zhou